Allarity Therapeutics terminates CEO James Cullem, appoints Thomas Jensen as CEO

Allarity Therapeutics, Inc.

James Cullem terminated as CEO and all other positions on December 8, 2023.
Thomas Jensen appointed CEO effective December 8, 2023; previously SVP of Investor Relations and IT.
Jensen co-founded Allarity Therapeutics A/S in 2004 and leads the Denmark laboratories.
Audit committee entered consulting agreement with Dr. Jeremy R. Graff for R&D advisory on small molecule inhibitors.
No material plan or arrangement yet in place for new CEO's compensation.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

James Cullem

Chief Executive Officer

ALLR · Allarity Therapeutics, Inc.

Effective: 2023-12-08
Successor: Thomas Jensen
Filed: December 11, 2023, 6:59 PM ET

On December 8, 2023, Mr. James Cullem was terminated as Chief Executive Officer of Allarity Therapeutics, Inc. (the “Company”) and all other positions with the Company and its subsidiaries.

Appointed

Thomas Jensen

Chief Executive Officer

ALLR · Allarity Therapeutics, Inc.

Effective: 2023-12-08
Filed: December 11, 2023, 6:59 PM ET

On December 8, 2023, Mr. Thomas Jensen, age 45, was appointed by the Company’s Board of Directors as Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

James Cullem was terminated as Chief Executive Officer at Allarity Therapeutics, Inc..

Action: terminated
Role: Chief Executive Officer

Exact text from the filing

On December 8, 2023, Mr. James Cullem was terminated as Chief Executive Officer of Allarity Therapeutics, Inc. (the “Company”) and all other positions with the Company and its subsidiaries.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Thomas Jensen was appointed as Chief Executive Officer at Allarity Therapeutics, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On December 8, 2023, Mr. Thomas Jensen, age 45, was appointed by the Company’s Board of Directors as Chief Executive Officer.

View on SEC.gov

Allarity Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-094535

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.